SOLODYN
PeakNDAORALTABLET, EXTENDED RELEASE
Approved
May 2006
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
6/8 — Strong
SOLODYN by Bausch + Lomb is 12. Approved for only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age, older. First approved in 2006.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SOLODYN is an extended-release oral tablet formulation of minocycline approved for acne treatment. While the exact mechanism of action and pharmacodynamics remain unknown, minocycline is a lipid-soluble tetracycline that distributes into skin and sebum. The extended-release formulation produces delayed absorption (Tmax 3.5–4.0 hours) compared to immediate-release minocycline products.
$0.004BPart D
Peak5.5 years to LOEProduct is at peak lifecycle stage with minimal Part D engagement (~62 claims in 2023), suggesting a mature, stable commercial footprint with smaller team requirements.
Mechanism of Action
12.1 Mechanism of Action The mechanism of action of SOLODYN for the treatment of acne is unknown. 12.2 Pharmacodynamics The pharmacodynamics of SOLODYN for the treatment of acne are unknown. 12.3 Pharmacokinetics SOLODYN Tablets are not bioequivalent to non-modified release minocycline products.…
Worked on SOLODYN at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.